Lysine is an essential amino acid in many important human functions, including the synthesis of proteins, the formation of collagen, helping to absorb calcium, and supporting the synthesis of hormones, enzymes, and antibodies. Furthermore, it aids in the healing of body parts after injuries or sickness, it is used for pig and poultry feeding. Supplementation with lysine in animal feed enhances nutrition and growth, as well as cost savings in the production of feeds. Fermentation using microorganisms such as Corynebacterium glutamicum is the usual procedure of production.
The Lysine Market is expected to grow with a significant CAGR of 7.51% during the forecast period (2025- 2033F). The Lysine market has seen rambling growth in recent years, driven by rising global meat consumption, increased demand for high-quality animal nutrition, and the cost-effectiveness of lysine in feed formulations. As the demand for global meat is increasing day by day, the need for lysine is also increasing. Additionally, lysine has discrete potential health benefits for humans, which include supporting the immune system and helping to prevent cold sores caused by the herpes virus. Additionally, advancements in fermentation technology and growing awareness about sustainable livestock farming are further fueling the expansion of the lysine industry worldwide.
For instance, on May 29, 2023, Evonik introduced a new generation of Biolys®, a proven source of lysine for livestock feeds. The novel formulation product contains valuable nutrients and energy resulting from its fermentation process, which benefits livestock such as swine or poultry. By formulation, the revised Biolys® contains 62.4 percent L-lysine (an 80 percent ratio to Lysine HCl) compared to the current version’s 60 percent L-lysine (a 77 percent ratio to Lysine HCl).
On May 25, 2022, Terremoto Biosciences, a biotechnology company that leveraged the power of lysine-based covalency to develop optimized medicines, announced to raised USD 75 million in a Series A financing. The round was co-led by OrbiMed and Third Rock Ventures. Proceeds from the financing will be used to advance Terremoto’s lysine-targeted covalency platform and develop best-in-class therapies against known drug targets, as well as first-in-class medicines against the previously undruggable.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook